Axsome v. Hetero: Solriamfetol Patent Suit Consolidated Into Eight-Case ANDA Action
Axsome Malta and Axsome Therapeutics brought a patent infringement action against Hetero USA and Hetero Labs in New Jersey over four patents protecting solriamfetol oral tablets. Within 132 days of filing, the case was consolidated with seven related actions, signalling a broad multi-defendant defence of the Sunosi franchise.
Four-Patent Solriamfetol Suit Folded Into Landmark ANDA Consolidation
On 11 January 2024, Axsome Malta Ltd. and Axsome Therapeutics Inc. filed suit against Hetero USA Inc., Hetero Labs Ltd., and Hetero Labs Limited in the District of New Jersey, asserting infringement of four patents — US11779554B1, US11771666B1, US11771667B1, and US11793776B1 — each tied to solriamfetol oral tablets at 75 mg and 150 mg base equivalents. Solriamfetol (marketed as Sunosi) is a dopamine and norepinephrine reuptake inhibitor approved for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea.
On 22 May 2024 — 132 days after filing — the case was not resolved on the merits but was consolidated by court order with seven related civil actions (Nos. 23-20354, 23-23255, 24-309, 24-860, 24-3999, 24-4002, and 24-4608) into a single consolidated proceeding. Consolidation covers discovery, case management, and trial, subject to further court order. No verdict, injunction, or damages determination was issued in this docket.
The consolidation of eight actions within four months of the latest filing suggests the district court is managing an unusually dense wave of ANDA challenges to the Sunosi patent estate. The breadth of the consolidated docket — spanning cases filed across late 2023 and 2024 — is consistent with multiple generic filers submitting Paragraph IV certifications against the same NDA, a pattern that typically precedes a substantive Hatch-Waxman trial. The precise list of generic challengers in the broader consolidated action, and their respective claim scope disputes, remain matters for the ongoing proceeding.
Filing to Case Consolidated in 132 days
132 days to consolidation — typical for coordinated ANDA multi-suit proceedings
Case consolidated: what the court order means for both parties
Consolidation is procedural — not a merits ruling
The court’s order consolidates eight civil actions ‘for all purposes, including discovery, case management, and trial.’ Under FRCP Rule 42(a), consolidation does not resolve any claim; it merges proceedings to avoid duplicative discovery and inconsistent rulings. All asserted patents and all named defendants remain in active dispute within the consolidated docket. No infringement finding, validity ruling, or damages assessment has been made.
No merits dispositionAxsome gains unified litigation leverage across all challengers
Consolidation typically favours the patent holder in ANDA litigation: Axsome can conduct discovery once across all generic filers, reducing cost and maintaining consistent claim construction positions. With four patents and at least eight related dockets, a single consolidated trial eliminates the risk of inconsistent verdicts on the same patent claims. Axsome retains the 30-month stay protection that typically attaches to timely-filed Hatch-Waxman suits.
Unified patent enforcementHetero and co-defendants face coordinated discovery burden
For Hetero and the other consolidated defendants, a single trial venue concentrates litigation risk. Generic filers may benefit from shared invalidity arguments and co-ordinated prior art searches, but they also face a more resourced plaintiff in a single forum. Any finding of infringement or validity in the consolidated trial will bind all named defendants simultaneously, raising the stakes for each party’s defence strategy.
Shared trial exposureSunosi market entry timeline remains uncertain for generics
Until the consolidated action produces a substantive ruling, no generic version of solriamfetol can be commercially launched without triggering patent infringement liability — unless the 30-month stay expires or a court-ordered delisting occurs. The consolidation of eight cases suggests multiple generic applicants are queued behind the same patent barrier, making the outcome of the merged proceeding commercially significant for the entire wakefulness-promoting drug segment.
Generic entry delayedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axsome Malta, Ltd. | Company | Pharmaceutical IP holding and commercial entity — holder of US11779554B1 and related solriamfetol patentsSearch in Eureka ↗ |
| Co-Plaintiff | Axsome Therapeutics, Inc. | Company | Search in Eureka ↗ |
| Defendant | Hetero USA, Inc. | Company | Generic pharmaceutical manufacturer and its US subsidiary; ANDA filer for solriamfetol tabletsSearch in Eureka ↗ |
| Co-Defendant | Hetero Labs, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Axsome Malta, Ltd.Search in Eureka ↗ |
| Defendant counsel | Kaan Ekiner | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant law firm | Cozen O’connor PC | Law Firm | Representing Hetero USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order names eight civil actions and merges them ‘for all purposes, including discovery, case management, and trial.’ This phrasing is substantively broad: it forecloses parallel discovery tracks and binds all parties to a single trial schedule. Critically, the order is explicitly ‘subject to further order of the Court,’ preserving the judge’s discretion to sever actions or create sub-groups if claim scope diverges significantly across defendants. No infringement or validity finding is embedded in this order.
US11779554B1 — Solriamfetol oral tablet formulations and dosing methods
The four asserted patents — US11779554B1, US11771666B1, US11771667B1, and US11793776B1 — all carry application numbers in the US18/1xxxxx series, suggesting a tight cluster of continuation or divisional filings from a common parent application. Each is designated as a granted utility patent (B1 suffix indicating first publication at grant). The patents are directed to solriamfetol, a Schedule IV controlled substance and dual dopamine/norepinephrine reuptake inhibitor indicated for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, marketed under the brand name Sunosi.
For competitors and ANDA filers, this cluster of closely related continuation patents represents a layered formulation and method-of-use barrier that is characteristic of late-stage brand pharmaceutical lifecycle management. Each patent may cover a distinct aspect of the product — formulation, dosing regimen, or therapeutic method — meaning invalidation of one patent leaves others intact. Companies developing wakefulness-promoting agents or reformulations of catecholaminergic compounds should treat this patent family as a high-priority clearance target.
Should you run an FTO against the Axsome solriamfetol patent family?
Any organisation developing a generic, reformulated, or therapeutically adjacent solriamfetol product — or a competing dopamine/norepinephrine reuptake inhibitor for sleep disorders — should conduct a freedom-to-operate analysis against all four asserted patents and their continuation family. The consolidation of eight ANDA cases confirms that multiple companies have already triggered Paragraph IV disputes with this patent estate. Understanding the claim scope of each patent before committing to an ANDA filing or NDA submission is essential.
PatSnap Eureka’s FTO Search Agent can map the full continuation family stemming from the US18/1xxxxx application cluster, identify the independent claims most likely to be asserted against competing formulations, and flag prosecution history estoppel that may limit claim scope. Eureka’s landscape view also surfaces design-around opportunities in the wakefulness and sleep-disorder therapeutic space — enabling R&D teams to route development away from the highest-risk claim boundaries before investment decisions are locked.
Run a freedom-to-operate analysis on US11779554B1 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA Cases Involving Wakefulness-Drug Patents in New Jersey
Explore related Paragraph IV patent infringement actions filed in the District of New Jersey involving wakefulness-promoting and sleep-disorder drug formulation patents.
What this case signals for the Hatch-Waxman ANDA litigation landscape
Multi-docket consolidation around a single NDA signals aggressive patent estate management — and a complex trial ahead.
Eight-case consolidation points to a dense Paragraph IV filing wave
When a district court consolidates eight ANDA actions in under six months, it consistently signals that multiple generic manufacturers filed Paragraph IV certifications against the same NDA near-simultaneously. For Axsome, this validates the commercial importance of the Sunosi franchise; for generic filers, it creates a crowded field where first-to-file exclusivity advantages are sharply contested.
Four patents in suit raise the invalidation burden for generic challengers
Asserting four patents — each with distinct application numbers — against a single generic product creates compounding invalidity challenges for defendants. Generic filers must overcome each patent independently. Even partial success (invalidating one or two patents) may not clear the path to launch if remaining asserted claims cover the approved formulation or dosage strengths.
Axsome v Hetero — key questions answered
The case was filed on 11 January 2024 in the District of New Jersey and closed on 22 May 2024 when it was consolidated by court order with seven related civil actions into a single proceeding. No merits ruling on infringement or patent validity was issued in this docket. The consolidated action covers discovery, case management, and trial.
Axsome asserted four patents: US11779554B1, US11771666B1, US11771667B1, and US11793776B1. All four are granted utility patents with application numbers in the US18/176xxx and US18/148xxx series, suggesting a close continuation family, and all relate to solriamfetol oral tablets at 75 mg and 150 mg base equivalent strengths.
Consolidation under FRCP Rule 42(a) merges the eight related actions for all purposes including discovery and trial. It does not resolve any patent claim. Hetero and the other consolidated defendants will face a single coordinated discovery process and a unified trial. Any claim construction, infringement finding, or invalidity ruling will apply across all consolidated defendants.
Eight civil actions in total were consolidated: Nos. 23-20354, 23-23255, 24-196 (this case), 24-309, 24-860, 24-3999, 24-4002, and 24-4608. The range of filing dates from late 2023 through 2024 is consistent with multiple generic manufacturers filing separate Paragraph IV certifications against the Sunosi NDA and triggering independent 30-month stay periods.
Solriamfetol (brand name Sunosi) is a Schedule IV dual dopamine and norepinephrine reuptake inhibitor approved by the FDA for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. Its commercial significance as a relatively recently approved wakefulness agent — combined with a layered continuation patent estate — makes it a high-value target for generic manufacturers seeking Paragraph IV certifications and early market entry.
PatSnap Eureka searches patents and litigation data to answer instantly.